» Articles » PMID: 35528009

Hashimoto Thyroiditis, Anti-Parietal Cell Antibodies: Associations With Autoimmune Diseases and Malignancies

Abstract

Background: Hashimoto thyroiditis (HT) is an autoimmune disease which may result in extensive damage of the thyroid gland. Chronic atrophic gastritis (CAG), is the most frequent HT-associated disorder, with anti-parietal cell autoantibodies (APCA) being a screening test for autoimmune CAG. The aim of this study was to investigate, in a cohort of HT patients: a) the prevalence of APCA in an attempt to define their clinical phenotype and b) any possible associations of APCA with other autoimmune diseases and malignancies.

Methods: This is a single-center, case-control study, conducted at a University Hospital. The study included patients with HT diagnosed between November 2017 and November 2020. Excluded were patients <18 years old, with sonographic features of HT but negative thyroid peroxidase (TPOAbs) or thyroglobulin autoantibodies (TgAbs), Graves' disease, Down or Turner's syndrome.

Results: A total of 840 patients with HT were included in the study, from whom 180 (21.4%) had positive APCA. A total of 79 patients (9.4%) had one or more organ-specific autoimmune diseases and 61 (7.3%) had a systemic autoimmune disease. Autoimmune diseases were more frequent in female than in male patients (17.9% versus 10.9%, p = 0.05). APCA-positive patients were older than APCA-negative (54.1 ± 13.5 versus 49.0 ± 14.6, p <0.001) and had more often positive TPOAbs (93.3% versus 83.9%, p=0.001). Gastric neoplasms were documented only in APCA-positive patients (p <0.001). A higher frequency of organ-specific autoimmune diseases was observed in the APCA-positive group (14.4% versus 8%, p = 0.024). In the subgroup of patients with additional autoimmune diseases (n = 140), younger age and positive APCA were independently associated with the presence of organ-specific autoimmunity (OR 0.954, 95% CI 0.927-0.982 and OR 3.100, 95% CI 1.256-7.652, respectively). Papillary thyroid cancer (PTC) occurred in 3.5% of patients (26/29 women). Positive family history for thyroid autoimmunity and negative TPOAbs were the only independent risk factors for PTC among women (OR 3.228, 95% CI 1.173-8.887 and 0.315, 95% 0.113-0.881, respectively).

Conclusion: This study reveals for the first time an association of APCA with organ-specific autoimmunity in HT patients. APCA together with patient age were independently associated with the presence of organ-specific autoimmunity. Finally, this study showed an association between APCA and gastric neoplasms in these patients.

Citing Articles

Monitoring the follow-up of autoimmune chronic atrophic gastritis using parietal cell antibodies and markers of gastric function.

Panozzo M, Antico A, Bizzaro N J Transl Autoimmun. 2025; 10:100273.

PMID: 39917315 PMC: 11800024. DOI: 10.1016/j.jtauto.2025.100273.


Circulating Autoantibodies in Adults with Hashimoto's Thyroiditis: New Insights from a Single-Center, Cross-Sectional Study.

Tripolino O, Mirabelli M, Misiti R, Torchia A, Casella D, Dragone F Diagnostics (Basel). 2024; 14(21).

PMID: 39518417 PMC: 11544974. DOI: 10.3390/diagnostics14212450.


Regulation of Treg cells by cytokine signaling and co-stimulatory molecules.

Zong Y, Deng K, Chong W Front Immunol. 2024; 15:1387975.

PMID: 38807592 PMC: 11131382. DOI: 10.3389/fimmu.2024.1387975.


Thyroid disorders and gastrointestinal dysmotility: an old association.

Xu G, Hu M, Li S, Ran X, Zhang H, Ding X Front Physiol. 2024; 15:1389113.

PMID: 38803365 PMC: 11129086. DOI: 10.3389/fphys.2024.1389113.


Thyroid Disease and Systemic Lupus Erythematosus.

Athanassiou L, Kostoglou-Athanassiou I, Kaiafa G, Tsakiridis P, Koukosias N, Mitsoulis S Medicina (Kaunas). 2023; 59(11).

PMID: 38003960 PMC: 10673127. DOI: 10.3390/medicina59111911.


References
1.
Tozzoli R, Kodermaz G, Perosa A, Tampoia M, Zucano A, Antico A . Autoantibodies to parietal cells as predictors of atrophic body gastritis: a five-year prospective study in patients with autoimmune thyroid diseases. Autoimmun Rev. 2010; 10(2):80-3. DOI: 10.1016/j.autrev.2010.08.006. View

2.
Utiyama S, De Bem R, Skare T, De Carvalho G, Teixeira L, Bertolazo M . Anti-parietal cell antibodies in patients with autoimmune thyroid diseases. J Endocrinol Invest. 2017; 41(5):523-529. DOI: 10.1007/s40618-017-0755-2. View

3.
Alexandraki K, Nikolaou A, Thomas D, Syriou V, Korkolopoulou P, Sougioultzis S . Are patients with autoimmune thyroid disease and autoimmune gastritis at risk of gastric neuroendocrine neoplasms type 1?. Clin Endocrinol (Oxf). 2013; 80(5):685-90. DOI: 10.1111/cen.12346. View

4.
Chibulcutean O, Gabor M, Frandes S, Mocan S, Dumitrascu D, Negovan A . Demographic, hematologic, and endoscopic differences between predominant corporeal and antral atrophic gastritis: A STROBE-Compliant study. Medicine (Baltimore). 2021; 100(49):e28062. PMC: 8663852. DOI: 10.1097/MD.0000000000028062. View

5.
Castoro C, Le Moli R, Arpi M, Tavarelli M, Sapuppo G, Frittitta L . Association of autoimmune thyroid diseases, chronic atrophic gastritis and gastric carcinoid: experience from a single institution. J Endocrinol Invest. 2016; 39(7):779-84. DOI: 10.1007/s40618-016-0445-5. View